General Information of Drug (ID: DM5PFIJ)

Drug Name
Givosiran Drug Info
Synonyms
1639325-43-1; N-[1,3-Bis[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]-2-[[3-[3-[5-[(2R,3R,4R,5R,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentanoylamino]propylamino]-3-oxopropoxy]methyl]propan-2-yl]-12-[(2R,4R)-4-hydroxy-2-methylpyrrolidin-1-yl]-12-oxododecanamide; Fitusiran; Givlaari; Givosiran [INN]; Givosiran [USAN]; Givosiran [USAN:INN]; ALN-AS1; UNII-ROV204583W; ROV204583W; WHO 10280
Indication
Disease Entry ICD 11 Status REF
Acute intermittent hepatic porphyria 5C58.11 Approved [1]
Cross-matching ID
PubChem CID
119058042
CAS Number
CAS 1639325-43-1
TTD Drug ID
DM5PFIJ
ACDINA Drug ID
D01125

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
ALAS1 messenger RNA (ALAS1 mRNA) TTG1FXO HEM1_HUMAN Inhibitor [1]

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019